图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
免疫学评论综述™
影响因子: 1.404 5年影响因子: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN 打印: 1040-8401
ISSN 在线: 2162-6472

免疫学评论综述™

DOI: 10.1615/CritRevImmunol.v18.i1-2.120
pages 109-119

Dendritic Cell-Based Immunotherapy of Prostate Cancer

M. L. Salgaller
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125;Northwest Biotherapeutics, LLC, 120 Northgate Plaza, Suite 219, Seattle, WA 98125
B. A. Tjoa
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125
P. A. Lodge
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125;Northwest Biotherapeutics, LLC, 120 Northgate Plaza, Suite 219, Seattle, WA 98125
H. Ragde
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125
G. Kenny
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125
A. Boynton
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125;Northwest Biotherapeutics, LLC, 120 Northgate Plaza, Suite 219, Seattle, WA 98125
G. P. Murphy
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125

ABSTRACT

The immunotherapy of cancer, based on eliciting or enhancing the body’s own capacity to mount an effective antitumor response, has produced encouraging early results in the areas of melanoma and renal-cell carcinoma. Such treatments utilizing dendritic cells (DC), immune cells that are excellent antigen presenters, are especially promising. We performed a phase I clinical trial assessing the administration of autologous DC pulsed with HLA-A0201 -specific prostate-specific membrane antigen (PSMA) for the treatment of 51 men with hormone-refractory prostate cancer. Participants were divided into five groups receiving four or five infusions of peptides alone (PSM-P1 or PSM-P2; group 1 and 2, respectively), autologous DC (group 3), or DC pulsed with PSM-P1 or P2 (group 4 and 5, respectively). No significant toxicity was observed. Immune reactivity against PSM-P2 was detected in HLA-A2+ patients infused with DC pulsed with PSM-P1 or -P2 (group 4 and 5). An average decrease in PSA was observed only in group 5. Seven partial responders were identified based on NPCP criteria + PSA. The excellent tolerance of this treatment approach, as well as the enhanced cellular responses, decreased PSA levels, and partial clinical responses in some patients suggests that it holds great potential in prostate cancer therapy.


Articles with similar content:

Autoimmune Hepatitis: Factors Involved in Initiation and Methods of Diagnosis and Treatment
Critical Reviews™ in Immunology, Vol.36, 2016, issue 5
Marilina Tampoia, Franco Dammacco, Gianfranco Lauletta, Fabio Pavone, Sabino Russi, Andrea Marzullo, Domenico Sansonno
Fluorescence Monitoring of a Topically Applied Liposomal Temoporfin Formulation and Photodynamic Therapy of Nonpigmented Skin Malignancies
Journal of Environmental Pathology, Toxicology and Oncology, Vol.26, 2007, issue 2
Linda Persson, Johan Axelsson, Tilmann Trebst, Stefan Andersson-Engels, Susanna Grafe, Jenny Svensson, Sune Svanberg, Ann Johansson, Katarina Svanberg, Niels Bendsoe
PART V. Modulation of Antitumor Vaccine Strategies
Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy

Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Philip M. Arlen, Jeffrey Schlom, Ravi A. Madan, James L. Gulley, James W. Hodge
Immune Responses to Water-Soluble Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) P. Karst. Polysaccharides in Patients with Advanced Colorectal Cancer
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Min Huang, Eli Chan, Wenbo Tang, Shufeng Zhou, Xihu Dai
Yellow Brain Culinary-Medicinal Mushroom, Tremella mesenterica Ritz.:Fr. (Higher Basidiomycetes), is Subjectively but not Objectively Effective for Eradication of Helicobacter pylori: A Prospective Controlled Trial
International Journal of Medicinal Mushrooms, Vol.14, 2012, issue 1
Ronit Gafni-Schieber, Solomon P. Wasser, Jesse Lachter, Yevgeny Yampolsky